Oropharyngeal Cancer

Quadrivalent human papillomavirus vaccine cost-effective oropharyngeal cancer prevention

Quadrivalent human papillomavirus vaccine cost-effective oropharyngeal cancer prevention

The potential costs and effectiveness of HPV4 vaccination versus no vaccination were compared in a theoretical cohort based on a cohort of 192,940 boys aged 12 years.

Prior to vaccine, most oropharyngeal cancers HPV+

Prior to vaccine, most oropharyngeal cancers HPV+

Most oropharyngeal cancers diagnosed in the U.S. between 1995 and 2005 tested positive for HPV.

U.S. oral HPV prevalence near 7%

U.S. oral HPV prevalence near 7%

Higher prevalence of oral HPV in men than women, and peaks at ages 30 to 34 years and 60 to 64 years correlate with trends in oropharyngeal squamous-cell carcinoma incidence.

Sign Up for Free e-newsletters